Orion Portfolio Solutions LLC Reduces Holdings in VanEck Pharmaceutical ETF (NASDAQ:PPH)

Orion Portfolio Solutions LLC cut its position in VanEck Pharmaceutical ETF (NASDAQ:PPH) by 3.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,880 shares of the company’s stock after selling 985 shares during the quarter. Orion Portfolio Solutions LLC owned 0.48% of VanEck Pharmaceutical ETF worth $2,578,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in VanEck Pharmaceutical ETF by 18.6% during the 4th quarter. JPMorgan Chase & Co. now owns 11,316 shares of the company’s stock valued at $976,000 after purchasing an additional 1,774 shares in the last quarter. Tidemark LLC boosted its stake in shares of VanEck Pharmaceutical ETF by 123.6% during the 4th quarter. Tidemark LLC now owns 1,183 shares of the company’s stock valued at $102,000 after buying an additional 654 shares during the last quarter. Commonwealth Equity Services LLC grew its position in shares of VanEck Pharmaceutical ETF by 3.6% during the fourth quarter. Commonwealth Equity Services LLC now owns 17,966 shares of the company’s stock worth $1,550,000 after buying an additional 631 shares in the last quarter. Independent Advisor Alliance increased its stake in shares of VanEck Pharmaceutical ETF by 19.8% in the fourth quarter. Independent Advisor Alliance now owns 58,398 shares of the company’s stock worth $5,039,000 after buying an additional 9,647 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in VanEck Pharmaceutical ETF in the fourth quarter valued at $1,323,000.

VanEck Pharmaceutical ETF Price Performance

Shares of PPH stock opened at $88.73 on Wednesday. The firm has a fifty day moving average of $90.90 and a two-hundred day moving average of $90.60. The firm has a market cap of $553.68 million, a P/E ratio of 27.82 and a beta of 0.72. VanEck Pharmaceutical ETF has a 1-year low of $84.48 and a 1-year high of $99.51.

VanEck Pharmaceutical ETF Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 4th. Investors of record on Tuesday, April 1st will be issued a $0.5245 dividend. This is a positive change from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.31. This represents a $2.10 annualized dividend and a yield of 2.36%. The ex-dividend date is Tuesday, April 1st.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.